NCT02807272 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 23
- group Id
- BG001
- value
- 12
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 4
- group Id
- BG005
- value
- 44
- units
- Participants
- groups
- description
- Participants with CMML received tipifarnib at a starting dose of 1200 mg, BID, for 7 days in alternating weeks (Days 1 to 7 and Days 15 to 21) in 28-day cycles.
- id
- BG000
- title
- KRAS/NRAS WT
- description
- Participants with CMML received tipifarnib at a starting dose of 1200 mg, BID, for 7 days in alternating weeks (Days 1 to 7 and Days 15 to 21) in 28-day cycles.
- id
- BG001
- title
- KRAS/NRAS Mut
- description
- Participants with CMML received tipifarnib at a starting dose of 1200 mg, BID, for 7 days in alternating weeks (Days 1 to 7 and Days 15 to 21) in 28-day cycles.
- id
- BG002
- title
- KRAS/NRAS Missing
- description
- Participants with MDS/MPN received tipifarnib at a starting dose of 400 mg, orally, BID on Day 1 through 21 of each 28-day treatment cycle.
- id
- BG003
- title
- CXCR4/2 High
- description
- Participants with MDS/MPN received tipifarnib at a starting dose of 400 mg, orally, BID on Day 1 through 21 of each 28-day treatment cycle.
- id
- BG004
- title
- CXCR4/2 Low
- description
- Total of all reporting groups
- id
- BG005
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 6.62
- value
- 70.0
- group Id
- BG001
- spread
- 6.68
- value
- 69.7
- group Id
- BG002
- spread
- 2.83
- value
- 76.0
- group Id
- BG003
- spread
- 2.89
- value
- 67.3
- group Id
- BG004
- spread
- 4.04
- value
- 70.5
- group Id
- BG005
- spread
- 6.14
- value
- 70.1
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 11
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 19
- title
- Female
- measurements
- group Id
- BG000
- value
- 12
- group Id
- BG001
- value
- 9
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 25
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 21
- group Id
- BG001
- value
- 12
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 41
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 3
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 20
- group Id
- BG001
- value
- 10
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 4
- group Id
- BG005
- value
- 38
- title
- White
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 3
- title
- Black or African American
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- title
- Native Hawaiian/other Pacific Islander
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 2
- title
- Asian
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- title
- American Indian/Alaska Native
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 1
- title
- Other
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
- population Description
- Full Analysis Set (FAS): All enrolled participants who received at least one dose of tipifarnib.
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 23
- group Id
- BG001
- value
- 12
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 4
- group Id
- BG005
- value
- 44
- units
- Participants
- groups
- description
- Participants with CMML received tipifarnib at a starting dose of 1200 mg, BID, for 7 days in alternating weeks (Days 1 to 7 and Days 15 to 21) in 28-day cycles.
- id
- BG000
- title
- KRAS/NRAS WT
- description
- Participants with CMML received tipifarnib at a starting dose of 1200 mg, BID, for 7 days in alternating weeks (Days 1 to 7 and Days 15 to 21) in 28-day cycles.
- id
- BG001
- title
- KRAS/NRAS Mut
- description
- Participants with CMML received tipifarnib at a starting dose of 1200 mg, BID, for 7 days in alternating weeks (Days 1 to 7 and Days 15 to 21) in 28-day cycles.
- id
- BG002
- title
- KRAS/NRAS Missing
- description
- Participants with MDS/MPN received tipifarnib at a starting dose of 400 mg, orally, BID on Day 1 through 21 of each 28-day treatment cycle.
- id
- BG003
- title
- CXCR4/2 High
- description
- Participants with MDS/MPN received tipifarnib at a starting dose of 400 mg, orally, BID on Day 1 through 21 of each 28-day treatment cycle.
- id
- BG004
- title
- CXCR4/2 Low
- description
- Total of all reporting groups
- id
- BG005
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 6.62
- value
- 70.0
- group Id
- BG001
- spread
- 6.68
- value
- 69.7
- group Id
- BG002
- spread
- 2.83
- value
- 76.0
- group Id
- BG003
- spread
- 2.89
- value
- 67.3
- group Id
- BG004
- spread
- 4.04
- value
- 70.5
- group Id
- BG005
- spread
- 6.14
- value
- 70.1
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 11
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 19
- title
- Female
- measurements
- group Id
- BG000
- value
- 12
- group Id
- BG001
- value
- 9
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 25
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 21
- group Id
- BG001
- value
- 12
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 41
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 3
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 20
- group Id
- BG001
- value
- 10
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 4
- group Id
- BG005
- value
- 38
- title
- White
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 3
- title
- Black or African American
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- title
- Native Hawaiian/other Pacific Islander
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 2
- title
- Asian
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- title
- American Indian/Alaska Native
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 1
- title
- Other
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
- population Description
- Full Analysis Set (FAS): All enrolled participants who received at least one dose of tipifarnib.
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle